Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors

Jian Li(National Center on Birth Defects and Developmental Disabilities), Lin Shen(Peking University), Aiping Zhou(National Cancer Center), Ying Yuan(Zhejiang Cancer Hospital), Shukui Qin(81th Hospital of PLA), Haolan Lu, Ting Xu(The University of Texas MD Anderson Cancer Center), Weijie Zhang(First Affiliated Hospital of Zhengzhou University), Jianwei Yang(Fujian Provincial Cancer Hospital), David Liu(Bristol-Myers Squibb (Germany)), Weijian Guo, Liangjun Zhu, Yanhong Deng(Sun Yat-sen University), John Gong, Silong Xiang
Journal of Hematology & Oncology
June 21, 2021
10.1186/s13045-021-01095-1
Cited by 149

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775